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Acute pancreatitis (AP) is a common and devastating inflammatory condition of the pancreas that is considered to be a paradigm of sterile inflammation leading to systemic multiple organ dysfunction syndrome (MODS) and death 1, 2 . Acute mortality from AP-MODS exceeds 20% (ref. 3) , and the lifespans of those who survive the initial episode are typically shorter than those of the general population 4 . There are no specific therapies available to protect individuals from AP-MODS. Here we show that kynurenine-3-monooxygenase (KMO), a key enzyme of tryptophan metabolism 5 , is central to the pathogenesis of AP-MODS. We created a mouse strain that is deficient for Kmo (encoding KMO) and that has a robust biochemical phenotype that protects against extrapancreatic tissue injury to the lung, kidney and liver in experimental AP-MODS. A medicinal chemistry strategy based on modifications of the kynurenine substrate led to the discovery of the oxazolidinone GSK180 as a potent and specific inhibitor of KMO. The binding mode of the inhibitor in the active site was confirmed by X-ray co-crystallography at 3.2 Å resolution. Treatment with GSK180 resulted in rapid changes in the levels of kynurenine pathway metabolites in vivo, and it afforded therapeutic protection against MODS in a rat model of AP. Our findings establish KMO inhibition as a novel therapeutic strategy in the treatment of AP-MODS, and they open up a new area for drug discovery in critical illness.
Systemic tryptophan metabolism in mammals occurs primarily via the kynurenine pathway ( Fig. 1a) 5 . Tryptophan metabolites contribute to acute lung injury in rats with AP 6 , and the tryptophan metabolite kynurenine is elevated in blood in humans with severe AP 6 . Sitting at a critical fork in the pathway, KMO metabolizes kynurenine to 3-hydroxykynurenine, which increases oxidative stress 7 , induces apoptosis 8 and is injurious to several cell types 9 . The inhibition of KMO should reduce 3-hydroxykynurenine production, which may therefore provide an efficacious strategy for preventing or reducing the severity of extrapancreatic organ injury in AP.
To explore the role of KMO in disease processes, we created a mouse strain that lacks KMO activity constitutively in all tissues (Supplementary Fig. 1a ). Anatomical mapping of tissue Kmo mRNA expression in wild-type C57BL6 mice showed high levels of Kmo expression in the liver and kidney and moderate Kmo mRNA expression in organs containing secondary lymphoid tissue, specifically the lung, spleen, mesenteric lymph node, thymus and peripheral lymph nodes (Supplementary Fig. 1b ). Mice that are homozygous for the Kmo knockout-first tm1a allele (hereafter referred to as Kmo null mice) were shown to have no detectable mRNA for Kmo in any tissues. Liver homogenates from Kmo null mice lacked the ability to convert kynurenine to 3-hydroxykynurenine, but this activity was restored to wild-type levels in mice in which the inserted stop signal had been removed (Kmo FRT-deleted mice), showing that the defect resulted from the specific engineered mutation (Supplementary Fig. 1c) .
We explored the pathways of kynurenine metabolism by measuring upstream, downstream and alternative pathway metabolites ( Fig. 1b-g) . When compared to Kmo FRT-deleted mice, Kmo null mice show equivalent steady-state tryptophan concentrations and profound depletion of 3-hydroxykynurenine ([tryptophan] plasma in Kmo FRT-deleted versus Kmo null mice, 28 ± 1 µM versus 28 ± 1 µM; P = 0.843 (t test); [3-hydroxykynurenine] plasma in Kmo FRT-deleted versus Kmo null mice, 32 ± 3 nM versus BLQ; P < 0.001 (t test); n = 5 per group). Kmo null mice have a 19-fold backlog of kynurenine upstream, which indicates that KMO is normally the predominant pathway for the metabolism of kynurenine ([kynurenine] plasma in Kmo FRT-deleted versus Kmo null mice, 0.6 ± 0.1 µM versus 11.0 ± 1.0 µM; P < 0.001 (t test), n = 5 per group). There is a preferential diversion of kynurenine metabolism to kynurenic acid in Kmo null mice, which show steady-state levels that are 81-fold higher than those in Kmo FRT-deleted mice ([kynurenic acid] plasma in Kmo FRT-deleted versus Kmo null mice, 0.1 ± 0.0 µM versus 11.0 ± 1.2 µM; P < 0.001 (t test); n = 5 per group). Metabolism of kynurenine can also bypass KMO through the action of kynureninase, which can convert kynurenine to anthranilic acid, which is in turn converted to 3-hydroxyanthranilic acid by nonspecific hydroxylase activity 5 . This pathway, however, was less active; it exhibited levels of anthranilic acid that were only fourfold higher in Kmo null mice than in Kmo FRT-deleted mice ([anthranilic acid] plasma in Kmo FRT-deleted versus Kmo null mice, 0.3 ± 0.1 µM versus 1.0 ± 0.1 µM; P < 0.001 (t test); n = 5 per group). Kmo null mice have reduced serum 3-hydroxyanthranilic acid concentrations in the steady state, although the reduction is less than that observed for 3-hydroxykynurenine ([3-hydroxyanthranilic acid] plasma in Kmo FRT-deleted versus Kmo null mice, 2.0 ± 0.3 µM versus 1.1 ± 0.2 µM; P = 0.034 (t test); n = 5 per group). These data support the idea that, under normal conditions, 3-hydroxyanthranilic acid is produced primarily via 3-hydroxykynurenine rather than via anthranilic acid, but they suggest that the pathway to bypass KMO can function to some degree when KMO is absent. Taken together, these data show that KMO is the key gatekeeper enzyme that determines the metabolic fate of kynurenine.
We next tested whether the absence of KMO activity affected extrapancreatic organ injury in experimental AP induced by the injection of taurocholate into the biliopancreatic duct during laparotomy (hereafter referred to as ' AP mice'). Pancreata from sham-operated mice showed normal architecture and no signs of inflammation, whereas those from AP mice showed evidence of necrosis, interlobular edema and a pronounced inflammatory cell infiltrate ( Supplementary Fig. 2a,b) . No difference in pancreatic injury was noted in Kmo null as compared to wild-type (Kmo wt ) control mice ( Fig. 2a ) (composite histological score Kmo wt sham versus AP, 0.0 ± 0.0 versus 7.1 ± 0.4; Kmo null sham versus AP, 0.0 ± 0.0 versus 7.3 ± 0.7; P < 0.001 by one-way analysis of variance (ANOVA) across all groups, post hoc Student-Neumann-Keuls (S-N-K) threshold P < 0.05 was significant for sham versus AP in both mouse strains; Kmo null AP versus Kmo wt AP was not significant (n.s.); n = 6 or 7 per group). Most infiltrating inflammatory cells were positive for the neutrophil marker myeloperoxidase (MPO), as measured by immunohistochemistry ( Supplementary Fig. 2b) , and we found no significant difference between Kmo null and Kmo wt mice with AP in the number of infiltrating neutrophils in the pancreas (Supplementary Fig. 2c ). There was no significant infiltrate of cells positive for the mouse monocyte marker F4/80 ( Supplementary  Fig. 2d ). Serum amylase concentration was substantially elevated in AP in both strains, but it was less so in Kmo null than in Kmo wt mice ( Supplementary Fig. 2e ).
Interleukin (IL)-6 trans-signaling has been reported to contribute to extrapancreatic organ injury in experimental mouse AP 10 , and indeed, serum IL-6 concentrations were elevated in AP mice compared to those in sham mice in both Kmo wt and Kmo null mice ( Supplementary  Fig. 3a ). There was no statistically significant rise in serum IL-10 levels in AP in either Kmo wt or Kmo null mice ( Supplementary Fig. 3b ). Kynurenine pathway metabolite levels confirmed the biochemical phenotype seen in unstressed mice and showed a small depletion of tryptophan as a result of AP ( Supplementary Fig. 3c-f ). npg l e t t e r s 2 0 4 VOLUME 22 | NUMBER 2 | FEBRUARY 2016 nature medicine
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The lung is the extrapancreatic organ system that is most commonly affected in humans with AP. Experimental AP in Kmo wt mice generated histological changes consistent with moderate acute respiratory distress syndrome, specifically the thickening of the alveolar walls characterized by the congestion of alveolar capillaries, interstitial edema and leukocyte infiltrates, and exudation of proteinaceous edema fluid into alveolar spaces. This pathology was still detectable to some degree in Kmo null mice with AP, although it was much less marked (Fig. 2b,c and Supplementary Fig. 4a-d) . MPO-positive infiltrating neutrophils in the lung were more numerous during AP in Kmo wt than in Kmo null mice ( Supplementary Fig. 4e) . Experimental AP increased the number of apoptotic cells in both strains, significantly so in Kmo wt mice ( Fig. 2d ) (Kmo wt sham versus AP, 3 ± 1 versus 21 ± 9 TUNEL-positive cells per 10 6 pixels; Kmo null sham versus AP, 2 ± 0 versus 6 ± 1 TUNEL-positive cells per 10 6 pixels; P = 0.033 by oneway ANOVA across all groups, post hoc S-N-K threshold of P < 0.05 was significant for Kmo wt sham versus AP and Kmo wt AP versus Kmo null AP; Kmo null sham versus AP, n.s.; n = 6 or 7 per group).
Acute kidney injury (AKI) frequently follows lung injury in a cumulative manner during AP-MODS 7 . Experimental AP led to a dramatic increase in kidney cell apoptosis, which was markedly lower in Kmo null mice than in Kmo wt controls ( Fig. 2e ) (Kmo wt sham versus AP, 2 ± 0 versus 18 ± 5 TUNEL-positive cells per 10 6 pixels; Kmo null sham versus AP, 1 ± 0 versus 6 ± 2 TUNEL-positive cells per 10 6 pixels; P = 0.001 by one-way ANOVA across all groups, post hoc S-N-K threshold of P < 0.05 was significant for Kmo wt sham versus AP and Kmo wt AP versus Kmo null AP; Kmo null sham versus AP, n.s.; n = 6 or 7 per group). There was no evidence of histological damage ( Supplementary  Fig. 5a-d ) or of inflammatory infiltrate ( Supplementary Fig. 5e,f) , and we found no significant functional impairment; creatinine levels were unchanged ( Fig. 2f ) ([creatinine] serum Kmo wt sham versus AP, 16 ± 5 versus 23 ± 5 mmol/liter; Kmo null sham versus AP, 5 ± 1 versus 9 ± 2 mmol/liter; P = 0.019 by one-way ANOVA across all groups, post hoc S-N-K threshold P < 0.05 n.s. for Kmo wt sham versus AP, for Kmo wt AP versus Kmo null AP or for Kmo null sham versus AP; n = 5-7 per group). The baseline serum creatinine in Kmo null mice was lower than that in Kmo wt mice, although this was not statistically significant.
Experimental AP induced a biochemical liver injury in Kmo wt and Kmo null mice, but when KMO activity was absent, the magnitude of the rise in alanine aminotransferase (ALT), a marker of hepatocyte necrosis, was significantly reduced ( Fig. 2g ) ([ALT] plasma Kmo wt sham versus AP, 49 ± 14 versus 672 ± 68 mmol/liter; Kmo null sham versus AP, 38 ± 4 versus 352 ± 36 mmol/liter; P < 0.001 by one-way ANOVA across all groups, post hoc S-N-K threshold of P < 0.05 was significant for sham versus AP in both strains and Kmo wt AP versus Kmo null AP; n = 5-7 per group).
In critically ill individuals, the intravenous route of drug administration is preferred because it provides both ease of administration and control. Several small-molecule KMO inhibitors have been reported in the literature for the potential treatment of Huntington's disease 8 , but they all lack the physicochemical properties that are required for the clinical development of an intravenous drug. Previous studies suggested that both the carboxylic acid and the carbonyl group present in kynurenine were required for KMO inhibition 11 . Therefore, a series of propanoic acid heterocycles were prepared, which contained H-bond accepting groups to mimic the role of the carbonyl functionality and led to the discovery of the oxazolidinone GSK180 ( Fig. 3a and Supplementary Note).
GSK180 has a low molecular weight (276 Da) and showed a halfmaximal inhibitory concentration (IC 50 ) of approximately 6 nM (mean ± s.d. pIC 50 (i.e., the negative logarithm of the IC 50 expressed in molar units) 8.2 ± 0.17 (n = 103)) in a human KMO biochemical assay using human KMO expressed as a GST-fusion protein in a baculovirus expression system 12 (Fig. 3b) . The observed potency of GSK180 decreased as the concentration of kynurenine was increased, which shows that the inhibition of KMO activity by GSK180 is competitive with the kynurenine substrate ( Supplementary Fig. 6a ). GSK180 showed negligible activity against other enzymes in the tryptophan pathway ( Supplementary Table 1 ), against a panel of more than 50 unrelated proteins ( Supplementary Table 2 ) and against an additional series of acidergic proteins ( Supplementary Table 3 ).
Human KMO was cloned and stably expressed in human embryonic kidney 293 (HEK293) cells, in which it conferred the ability to convert kynurenine to 3-hydroxykynurenine, with an apparent Michaelis constant (K m ) for kynurenine of 78 ± 12 µM ( Supplementary Fig. 6b ). GSK180 has a mean IC 50 of 2.0 µM in this cell-based assay (mean pIC 50 5.7 ± 0.15 (n = 4)) ( Fig. 3b) . Primary human hepatocytes possess endogenous KMO activity, and GSK180 inhibited this activity with comparable potency (IC 50 = 2.6 µM) (Fig. 3b) . npg this experiment were too low to be accurately measured. The changes observed in kynurenine are exactly as expected, but the change in kynurenic acid is curious, because its peak occurs before the peak of kynurenine; this suggests that the increase seen is not simply a result of the increase in availability of the substrate.
To explore whether the changes in metabolites observed in the presence of drug were due to the inhibition of KMO alone or whether they were mediated by another mechanism, GSK180 was dosed to Kmo wt and Kmo null mice as a single bolus injection at 30 mg/kg, which delivered plasma drug levels 1 h after dosage of 263 ± 98 µM and 351 ± 87 µM, respectively. The administration of GSK180 resulted in an increase in kynurenine in Kmo wt mice, but no change was seen in the Kmo null mice, which confirms that this increase results from the inhibition of KMO (Supplementary Fig. 6d ). Notably, GSK180 caused a substantial reduction in circulating tryptophan levels in both Kmo wt and Kmo null mice, suggesting that the compound had an additional effect unrelated to KMO inhibition. Moreover, a clear increase in kynurenic acid was also observed in the Kmo null mice, suggesting that the changes observed in kynurenic acid in the presence of the compound result from both metabolic diversion caused by KMO inhibition and an effect on kynurenic acid metabolism that is not mediated by KMO (Supplementary Fig. 6d ).
After further investigation, we confirmed that a similar drop in circulating tryptophan was seen in rats, and moreover, that it occurred immediately after compound administration and that it was stable for several hours, recovering slowly as the plasma level of the compound dropped below 300 µM ( Supplementary Fig. 6e ). Tryptophan is the only amino acid that is bound to plasma proteins, and high concentrations of drugs such as salicylate have been shown to compete with this binding 14 . Indeed, GSK180 showed a concentration-dependent displacement of tryptophan from plasma proteins in the range equivalent to the exposures observed in this study ( Supplementary Table 4 ). However, the free-tryptophan level remains constant (40 µM (22% of 180 µM) in control rats and 42 µM (60% of 70 µM) directly after high aqueous solubility of 24 mg/ml in saline and high microsomal metabolic stability across species (clearance < 0.5 ml/min/g in rat, dog and human tissue) (data not shown). After bolus intravenous (i.v.) injection into rats, GSK180 showed a low volume of distribution and low clearance (Vd ss (volume of distribution at steady state) 0.14 liters/kg, t 1/2 (half-time for elimination of the drug from the systemic compartment during the terminal phase of the pharmacokinetic profile) 3 h, Clp (volume of plasma that is completely cleared of drug per unit of time) 0.45 ml/min/kg at 27 mg/kg i.v. dose) ( Fig. 3c) . Thus GSK180 is a highly selective KMO inhibitor with properties suitable for i.v. administration. The structure of human KMO remains elusive, but that of the yeast ortholog has recently been reported 13 . We used KMO from Pseudomonas fluorescens, in which all the residues that surround the catalytic site are conserved compared to human KMO, with the exception of HIS320, which is a phenylalanine in the human protein.
Despite this level of conservation, GSK180 demonstrated significantly lower potency against P. fluorescens compared to the human construct (IC 50 = 500 nM versus 6 nM, respectively). Nonetheless, a 3.2 Å resolution co-crystal structure of GSK180 bound to P. fluorescens KMO was solved, and significant interactions were revealed within the catalytic site (Fig. 3d) . The carboxylate forms a salt bridge with Arg84 and forms hydrogen bonds with the side chains of Tyr98 and Asn369. The oxazolidinone carbonyl forms a hydrogen bond with the side chain of the C-terminal domain residue Tyr404, and the 5-chlorine atom forms a π-interaction with Phe238.
Rat Kmo was expressed in HEK cells in a manner exactly analogous to the human enzyme described above; the activity showed an apparent K m for kynurenine of 258 ± 121 µM ( Supplementary  Fig. 6c ). GSK180 inhibited rat KMO slightly less potently than it did the human enzyme, giving an IC 50 of 7 µM (mean pIC 50 5.2 ± 0.09 (n = 5)) ( Fig. 3b) . When dosed to rats as an i.v. bolus at 27 mg/kg, the initial concentration of GSK180 was nearly 600 µM in blood (Fig. 3c) . GSK180 is excluded from rat erythrocytes (blood:plasma ratio of 0.46), and it is moderately bound to rat plasma proteins (free fraction 7.7% at 1 mM, n = 2), meaning that the peak free drug levels in plasma (92 µM) are >12-fold above the IC 50 in cells. Indeed, treatment with GSK180 resulted in a rapid increase in the circulating levels of both kynurenine and kynurenic acid, which returned to baseline as the drug levels dropped (Fig. 3c) . Levels of 3-hydroxykynurenine in compound administration), which suggests that the displaced tryptophan is distributing rapidly into tissues.
Despite the confounding effects of GSK180 on the pathway outside of KMO inhibition, the dynamics of the change in kynurenine seen after inhibition demonstrate that, even under resting conditions, flux through KMO is rapid. This result is thus consistent with a role for tryptophan metabolism via KMO as an important and early contributory mechanism in AP-MODS.
We next tested the efficacy of GSK180 in protecting against AP-MODS in a well-validated rat model of AP that generates secondary organ dysfunction within 6 h of the initial insult 6 . GSK180 was given in a therapeutic setting 1 h after the induction of AP as an i.v. bolus of 24 mg/kg, followed by an i.v. infusion of 5.5 mg/kg/h. This delivered stable plasma drug levels of approximately 600 µM throughout the experiment, which resulted in biochemical changes consistent with those seen in the Kmo null mouse and in unchallenged animals-namely, increased plasma kynurenine and kynurenic acid and decreased plasma tryptophan and 3-hydroxykynurenine ( Supplementary Fig. 7a ).
The experimental model induced pancreatic acinar cell necrosis, edema and an inflammatory cell infiltrate (Supplementary Fig. 7b-d) , with elevated serum amylase at 6 h (Supplementary Fig. 7e ). The severity of the histological injury and the magnitude of the serum amylase rise were equivalent in both AP and GSK180-treated groups ( Fig. 4a and Supplementary Fig. 7e) . The intense inflammatory cell infiltrate in AP consisted of MPO-positive neutrophils and monocytes positive for the ED1 antigen, the rat ortholog of CD68, which were present to the same extent in the pancreas tissue of rats with induced AP and rats with induced AP treated with GSK180 (AP + GSK180) ( Supplementary Fig. 7d,f) .
AP-MODS was associated with an acute rise in ALT, indicating hepatocyte injury, which was small in magnitude and equivalent in AP and in AP + GSK180-treated rats; both groups of rats with AP became relatively hypoglycemic compared to sham-operated controls, whereas serum albumin concentrations were affected only marginally (Supplementary Fig. 7g-i ). An elevation in systemic IL-6 concentrations was seen in experimental AP, which was of lesser magnitude in AP + GSK180-treated rats (Supplementary Fig. 7j) . Notably, IL-10 concentrations were marginally but not statistically significantly higher in AP rats, whereas they were higher still, and significantly so, in rats with AP treated with GSK180 (P = 0.0001 by one-way ANOVA, post hoc S-N-K threshold of P < 0.05) (Supplementary Fig. 7k ).
Acute lung injury (ALI) with features consistent with acute respiratory distress syndrome (ARDS) was observed on histological sections of lung tissue from rats with AP ( Fig. 4b and Supplementary  Fig. 8a-c) . They also showed an increase in neutrophilic inflammation (Fig. 4c,d) , lung protein leak (measured as an increase in total protein concentration in bronchoalveolar fluid six hours after the start of AP (BAL 6h )) ( Fig. 4e) , an increase in the circulating serum concentration of Krebs von den Lungen 6 (KL-6) (a type 2 pneumocyte MUC1-like glycoprotein and a marker of incipient ALI in humans 15, 16 ) ( Fig. 4f ) and increased apoptosis ( Fig. 4g and Supplementary Fig. 8d ). All these features of ALI were essentially prevented by treatment with GSK180 ([total protein] BAL 6h in sham versus AP versus AP + GSK180 rats, 245 ± 18 mg/liter versus 332 ± 18 mg/liter versus 142 ± 6 mg/ liter; P < 0.001 by one-way ANOVA across all groups, post hoc S-N-K threshold of P < 0.05 was significant between all groups; n = 7 or 8 rats per group; [KL-6] serum 6h in sham versus AP versus AP + GSK180 rats, 12 ± 1 ng/ml versus 39 ± 3 ng/ml versus 16 ± 2 ng per ml; P < 0.001 one-way ANOVA across all groups, post hoc S-N-K threshold of P < 0.05 was significant for sham versus AP and AP versus AP + GSK180, sham versus AP + GSK180 n.s.; n = 7 or 8 per group; sham versus AP versus AP + GSK180 rats, 0.9 ± 0.2 versus 3.3 ± 0.7 versus 1.7 ± 0.4 TUNEL-positive cells per 10 6 pixels; P = 0.004 by one-way ANOVA across all groups, post hoc S-N-K threshold of P < 0.05 was significant for sham versus AP and AP versus AP + GSK180, sham versus AP + GSK180 n.s.; n = 7 or 8 rats per group (sham versus AP versus AP + GSK180 rats, 97 ± 20 versus 180 ± 21 versus 105 ± 70 MPO-positive cells per 10 6 pixels; P = 0.011 by one-way ANOVA across all groups, post hoc S-N-K threshold of P < 0.05 was significant for sham versus AP and AP versus AP + GSK180, sham versus AP + GSK180 n.s.; n = 7 or 8 rats per group). Of note, an infiltrating population of ED1positive cells was present in the lung tissue of both AP groups, and it was significantly elevated in rats with AP treated with GSK180 (P = 0.003 by one-way ANOVA, post hoc S-N-K threshold of P < 0.05) (Supplementary Fig. 8e ).
Experimentally induced AP in rats resulted in a significant increase in TUNEL-positive renal tubular cells per unit area of tissue in the outer medullary stripe (the key anatomical region for acute tubular injury 17 ) ( Fig. 4h ) (sham versus AP versus AP + GSK180 rats, 1.3 ± 0.5 versus 7.4 ± 1.3 versus 2.1 ± 0.3 TUNEL-positive cells per 10 6 pixels; P < 0.001 by one-way ANOVA across all groups, post hoc S-N-K threshold of P < 0.05 was significant for sham versus AP and AP versus AP + GSK180, sham versus AP + GSK180 n.s.; n = 7 or 8 rats per group). There was no evidence of histological damage ( Supplementary  Fig. 9a-c) or of inflammatory infiltrate (Supplementary Fig. 9d) , but in the rat model of AP, we observed a significant loss of renal function as evidenced by elevated serum creatinine and urea at 6 h after AP induction (Fig. 4i,j) . Therapeutic administration of GSK180 in AP protected against all aspects of this kidney injury ([creatinine] serum 6h in sham versus AP versus AP + GSK180 rats, 23 ± 2 mmol/liter versus 52 ± 8 mmol/liter versus 29 ± 5 mmol/liter; P = 0.007 by one-way ANOVA across all groups, post hoc S-N-K threshold of P < 0.05 was significant for sham versus AP and AP versus AP + GSK180, sham versus AP + GSK180 n.s.; [urea] serum 6h in sham versus AP versus AP + GSK180 rats, 8.2 ± 0.5 mmol/liter versus 13.4 ± 0.9 mmol/liter versus 10.7 ± 0.8 mmol/liter; P < 0.001 by one-way ANOVA across all groups, post hoc S-N-K threshold of P < 0.05 was significant between all groups; n = 7 or 8 rats per group). A modest but statistically significant increase in ED1-positive cell counts in the kidneys of rats with AP treated with GSK180 was observed (P = 0.003 by one-way ANOVA, post hoc S-N-K threshold of P < 0.05) (Supplementary Fig. 9e) .
The development of MODS (and particularly of ARDS) is a key determinant of outcome in critically ill individuals, regardless of the initiating event 4 . AP serves as a paradigm for sterile systemic inflammation, and this work builds on a rapidly expanding body of work that is uncovering the potential role of the kynurenine pathway in several inflammatory and degenerative disease states, and it is the first to demonstrate therapeutic efficacy of KMO inhibition as protection against MODS.
Increased tryptophan metabolism through the kynurenine pathway has been detected in systemic inflammation in humans during AP 6 , trauma 18, 19 , coronary artery bypass surgery 20 , sepsis 21 and chronic renal failure 22 . Oxidative stress and apoptotic cell death mediated by 3-hydroxykynurenine have been proposed as drivers of disease 22, 23 . How 3-hydroxykynurenine results in tissue injury in AP is yet to be fully elucidated, but inference can be made from related experiments. In primary cultured neurons, 3-hydroxykynurenine causes cell death by apoptosis by producing reactive oxygen species, including superoxide radicals and hydrogen peroxide (H 2 O 2 ) 24, 25 , which can be counteracted l e t t e r s nature medicine VOLUME 22 | NUMBER 2 | FEBRUARY 2016 2 0 7 by antioxidants 26 or by blockade of intracellular peroxidase activity 24 . Furthermore, the oxidation product of 3-hydroxykynurenine itself, a short-lived quinone-imine, is highly reactive with the thiol and amine groups of proteins 27 . KMO inhibition increases plasma concentrations of kynurenic acid, which could be protective, but may also be harmful, in the context of AP. Kynurenic acid activates the G protein-coupled receptor GP35, and in so doing, inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF) release from human peripheral blood mononuclear cells 28 . In mice given a near-lethal dose of LPS, kynurenic acid administration prevents TNF release and reduces lethality 29 . Kynurenic acid elevation during KMO blockade may also therefore contribute to the benefit seen in Kmo null mice with AP and GSK180treated rats with AP by exerting an anti-inflammatory effect on innate immune cells. Kynurenic acid elevates the seizure threshold of mice and rats given intracerebral quinolinic acid by potent antagonism at the glycine allosteric site of the N-methyl-D-aspartate (NMDA) receptor complex; a KMO inhibitor may therefore be sedative.
The mechanisms that lead to increased levels of kynurenine pathway metabolites during sterile systemic inflammation are complex. Certainly, it is clear that increased kynurenine substrate is made available through increased indoleamine-2,3-dioxygenase (IDO) activity in extrahepatic tissues 30 . IDO is profoundly upregulated by bacterial LPS and pro-inflammatory cytokines, in particular, by gamma interferon (IFN-γ) (ref. 30 ). Furthermore, inflammationinduced tryptophan-2,3-dioxygenase activity, resulting in increased levels of kynurenine, regulates the induction of tolerance to LPS, and it is dependent on IDO activity 31 . These orthodox inflammatory signals also upregulate KMO activity in human monocytes 32 and in monocyte-derived macrophages 33 . Human monocytes show increased gene expression of IDO1, KMO and quinolinate phosphoribosyltransferase (QPRT, a gene encoding an enzyme downstream in the kynurenine pathway) when incubated with IFN-γ, and KMO expression correlates with kynurenine pathway activation as measured by the tryptophan:kynurenine ratio 34 .
IL-1β is also reported to drive upregulated KMO mRNA expression 35 . Interestingly, the induction of IDO expression in vitro in response to the toll-like receptor agonists LPS and CpG has been shown to be dependent on the presence of a functioning aryl hydrocarbon receptor (AhR) complex 36, 37 . Furthermore, kynurenine is now regarded as an AhR ligand, and as a whole, this complex is a key mechanistic contributor to endotoxin tolerance 31, 38 . Exogenous kynurenine added in co-culture of dendritic cells with T lymphocytes rescues a type 1 T regulatory phenotype, limits T helper 17 (T H 17) cell induction and reduces T H 17 cytokine release in an AhR-null system, when compared to AhR-competent co-cultures 36 . This is congruent with the observation that the presence of kynurenine during combined CD3 and CD28-specific antibody-induced T cell proliferation decreases the overall proliferation 38 and increases the proportion of forkhead box P3 (FOXP3) + T regulatory cells generated 37 . It is possible, although yet to be explicitly defined, that these adaptive, immune cell-mediated mechanisms may contribute to the efficacy of KMO inhibition shown in our experiments. Furthermore, the increase in kynurenine as a consequence of KMO inhibition may also contribute to free-radical scavenging. Experimentally, the addition of kynurenine scavenges hydrogen peroxide and, to a lesser extent, superoxide radical, and it has a concentration-dependent inhibitory effect on the production of reactive oxygen species by activated neutrophils, without directly affecting nicotinamide adenine dinucleotide phosphate (NADPH) oxidase function or phagocytosis 39 .
In Kmo null mice, fecundity, fertility and longevity up to 2 years of age are not affected, from which we can infer that prolonged KMO blockade and consequent chronic exposure to significantly elevated concentrations of kynurenic acid and kynurenine is well tolerated, at least in adapted mice. Independently, other researchers 40 have generated a second Kmo null mouse strain. This strain has an identical biochemical phenotype to the Kmo null mouse strain generated by us using Kmo null mouse embryonic stem cells engineered by the International Knockout Mouse Project (iKOMP). When considered together, the clear biochemical phenotypic changes in these two independently generated Kmo null mice strains demonstrate unequivocally that KMO activity defines the metabolic fate of kynurenine.
GSK180 is a potent inhibitor of isolated KMO, but it is less potent in the cellular context. The passive permeability of GSK180 across an artificial membrane was measured and found to be extremely low (<3 × 10 −6 cm s −1 ; n = 3), and measurement of drug concentration confirms that the intracellular level is more than 30 times lower than the extracellular concentration. It therefore seems reasonable to conclude that the lower potency observed in the cell-based assay is based on poor access by the compound to the intracellular compartment, necessitating higher drug levels to show pharmacodynamic activity. This leads to the unwanted (non-KMO-mediated) effects on tryptophan and kynurenic acid; used carefully, however, GSK180 remains a useful tool for probing the therapeutic potential of KMO inhibition. Improving cell potency will be a key component of the search for a clinical candidate.
AP-MODS is an early event in the overall disease course of AP, occurring in the first few hours to days after the onset of symptoms 3, 7 . If we are to rationalize KMO activity as a key contributor to AP-MODS, tryptophan and kynurenine metabolism must be rapid and occur within the expected timeframe of the onset of AP-MODS. The rate of change in metabolite levels after the administration of GSK180 strongly supports this, and it provides convincing evidence that kynurenine metabolism occurs in a disease-relevant time course, and that tryptophan is continuously metabolized and replenished to the plasma compartment on a large scale. Importantly, this rate of metabolic flux is well within the proposed timescale of tryptophan metabolism via KMO as an important and early contributory mechanism in AP-MODS. In addition, because KMO inhibition protects against extrapancreatic organ injury without a need to diminish the severity of the initiating pancreatic tissue damage, the clinical applicability is enhanced.
In conclusion, our experiments demonstrate a novel contributory metabolic mechanism of remote organ injury triggered by sterile initiators of systemic inflammation. Moreover, we have also shown that the metabolic target, KMO, is susceptible to therapeutic blockade. Together, these data strongly support a therapeutic role for KMO inhibitors in critical illness. Our findings therefore establish KMO inhibition as a novel therapeutic strategy in AP-MODS and possibly in other severe acute systemic inflammation.
MeTHODS
Methods and any associated references are available in the online version of the paper. Accession codes. Protein Data Bank: The final model of the crystal structure presented in Figure 3d has been deposited with accession code 5fn0.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
In vitro KMO inhibition assay. The inhibition of KMO activity was determined as previously described 12 . Briefly, full-length human KMO was expressed as a GST fusion in Sf9 cells (obtained from EACC, catalog number 89070101; tested for mycoplasma according to the ATCC Universal Mycoplasma detection protocol, catalog number 30-1012K when each vial was drawn for propagation) and used as a membrane suspension. Reactions were run at saturating NADPH (200 µM) and around K m for kynurenine (10 µM) in a buffer of 50 mM HEPES (pH 7.5), 2 mM DTT, 1 mM EDTA, 100 µM CHAPS and stopped after 2 h by the addition of trifluoroacetic acid (TFA). Plates were read on a RapidFire 200 autosampler/solid-phase extraction system (Agilent Technologies) coupled to a Sciex API4000 triple-quadrupole mass spectrometer (Applied Biosystems) operated in positive ion mode. Multiple reaction monitoring was used to detect both kynurenine and 3-hydroxykynurenine.
Cellular KMO enzyme inhibition assay. Full-length human KMO (GenBank Accession number NM_003679) was prepared as a synthetic gene (GenScript) and ligated into pcDNA5/FRT/V5-His-TOPO (Invitrogen). HEK293 cells (Flp-In-293 cells, Invitrogen) were co-transfected with the resulting recombinant KMO vector and pOG55 (Invitrogen), and grown in the presence of hygromycin to generate the stable HEK293-huKMO cell line. The authenticity of each stable HEK293 cell line was confirmed by STR profiling (Identicell, Denmark). HEK293-huKMO cells were grown in a 96-well microplate in DMEM medium containing 1% glutamine, 1% penicillin-streptomycin and incubated in 5% CO 2 , 95% O 2 at 37 °C. Serial dilutions of compound were prepared in 10% DMSO from a 10 mM stock solution in 100% DMSO. In a V-bottomed microplate, GSK180 at an appropriate concentration was added in duplicate at up to ten different concentrations. For low-inhibition controls, 1% DMSO was added to the microplate and for high-inhibition controls, 10 mM 6-(3,4-dichlorophenyl)pyrimidine-4-carboxylic acid (CAS Number 1207723-55-4) was added. The medium from the cells was removed, and a solution of Opti-MEM medium containing 1% glutamine, 1% penicillin/streptomycin and 200 µM l-kynurenine was added to the compound and control wells and incubated in 5% CO 2 , 95% O 2 at 37 °C for 20 h. After incubation, the medium was transferred to a deep well block containing acetonitrile and d5-tryptophan, centrifuged at 4 °C to remove debris and dried under nitrogen at 65 °C for 1 h. Residues were re-suspended in water/methanol (70:30) before LC-MS/MS analysis. LC-MS/MS analysis was carried out on a TSQ Quantum Discovery Triple Quadrupole Mass Spectrometer (ThermoFisher) coupled to an Aria CTC Autosampler and HPLC system (ThermoFisher). Separation was carried out on an Allure Biphenyl column at 50 °C using a water/methanol gradient (30% to 70% methanol over 30 s, held at 70% methanol for 60 s, then returned to 30% methanol over 120 s and re-equilibrated at 30% methanol for 60 s). The peak area ratio for 3-hydroxykynurenine/d 5 -tryptophan was used to determine the percentage inhibition. Data were fitted to the 4-parameter logistic equation (Y = bottom + (top-bottom)/(1 + 10^((logEC 50 − X) × HillSlope))) using GraphPad Prism software.
Freshly prepared human primary hepatocytes (Biopredict, France) were incubated overnight with compounds diluted in Williams's E basal media (Invitrogen) containing 10% FBS, 100 nM dexamethasone and 400 µM l-tryptophan (Sigma). After incubation, LC-MS/MS analysis was carried out on cell supernatant to detect and quantify metabolites. For presentation, the percentage inhibition was calculated using the observed increase in kynurenine, normalized to 100%. Data were fitted to the 4-parameter logistic equation (Y = bottom + (top-bottom)/ (1 + 10^((logEC 50 − X) × HillSlope))) using GraphPad Prism software.
Cellular K m determination. HEK293 cells stably transfected with either human KMO or rat Kmo were plated at 2 × 10 4 cells per well in 96-well poly-D-lysinecoated 96-well flat-bottomed microplates. Opti-MEM medium containing 1% glutamine, 1% penicillin/streptomycin and supplemented with varying concentrations of l-kynurenine (0-2,000 µM) was added, and the cells were incubated in 5% CO 2 , 95% O 2 at 37 °C for between 8 h and 20 h such that turnover was less than 15% across all concentrations. Each concentration of l-kynurenine was added in duplicate. The cell supernatants were removed and analyzed by LC-MS/MS to determine the amount of 3-hydroxykynurenine generated. The mean data for each independent experiment were fitted to the Michaelis-Menten equation (Y = V max × X/(K m + X)) using GraphPad Prism software.
Tryptophan pathway inhibition assays. Synthetic genes for full-length human kynureninase (KYNU) and kynurenine amino transferase types 1 and 2 (KATI and KATII) were generated and ligated into the vector pET24b such that C-terminal six histidine-tagged proteins were expressed in the Escherichia coli strain BL21(DE3)pLysS. For KATI and KATII, E. coli were grown to OD600 = 0.6 at 37 °C with shaking and induced with 0.1 mM IPTG for 4 h. For KYNU, E. coli were grown in ZYP-5052 auto-induction media 47 at 37 °C for 20 h. Cells were harvested and lysed by sonication. N-laurylsarcosine was added to the KATII cell lysate to final concentration of 2% v/v and mixed by vortexing. 
